Index Pharmaceuticals Holding AB (INDEX)

Overview

InDex Pharmaceuticals Holding AB (publ) is a pharmaceutical development company based in Solna, Sweden, focusing on creating solutions for patients suffering from ulcerative colitis, a chronic and often debilitating inflammatory bowel disease. Established in the year 2000, InDex Pharmaceuticals has committed itself to the development of novel therapies aimed at treating immunological diseases with a primary focus on ulcerative colitis. At the heart of its innovative efforts is the advancement of drug candidates through clinical trials, with its flagship drug, Cobitolimod, currently in phase III clinical development targeting moderate to severe ulcerative colitis.

Products and Services

InDex Pharmaceuticals Holding AB (publ) has developed a pipeline of pharmaceutical products and drug candidates with the potential to offer new treatment options for patients with various immunological diseases. The major highlights include:

• Cobitolimod: This is the lead drug candidate of InDex Pharmaceuticals, which is in phase III clinical development specifically for patients suffering from moderate to severe ulcerative colitis. Cobitolimod is a topically acting DNA-based immunomodulatory sequence (DIMS) that aims to provide a novel mechanism of action in the management of this challenging condition by targeting the inflammation directly at the site of the disease in the colon.
• DNA based immunomodulatory sequences: Besides Cobitolimod, InDex Pharmaceuticals is also in the process of developing a broad portfolio of DNA based immunomodulatory sequences that are designed to modulate the immune system in various ways. These sequences are being studied for their potential in treating a range of immunological diseases, leveraging the innate immune system to restore a healthy balance and combat diseases.